Skip to main content
Livermore
Livermore
US stocksTW
ZHEN

Prelude Therapeutics Inc

PRLD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001678660

No open-market purchases or sales by Prelude Therapeutics Inc insiders were filed in the last 90 days; 75 institutions reported holding it in 13F filings for Q2 2026, worth $264.3M in total; no superinvestor holds it.

Holders of 5% or more of PRLD

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Prelude Therapeutics Inc, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of PRLD
HolderLatest formStakeChangeFirst filedLatest filingFiling
OrbiMed Advisors LLC13D/A16.00%12.9M shares–Jan 14, 20213 filingsApr 23, 2026SEC
Baker Bros. Advisors LP13D/A15.50%10.3M shares−8.00 ppfrom 23.50%Jan 29, 20215 filingsApr 22, 2026SEC
Vaddi Krishna13G/A13.15%6.75M shares−0.65 ppfrom 13.80%Feb 11, 20217 filingsFeb 13, 2026SEC
Ra Capital Management, L.P.13G9.90%6.48M sharesNewApr 28, 20261 filingApr 28, 2026SEC
Incyte Corp13G9.90%4.37M sharesNewNov 7, 20251 filingNov 7, 2025SEC
Soleus Private Equity Fund III, L.P.13G5.20%3.38M sharesNewJul 8, 20261 filingJul 8, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

29 Schedule 13D and 13G filings on Prelude Therapeutics Inc, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on PRLD
Filed (ET)FilerFormStakeChangeEvent dateFiling
Jul 8, 20265:20 PM ETSoleus Private Equity Fund III, L.P.and 8 others13G5.20%3.38M sharesNewApr 21, 2026SEC
Apr 28, 20265:16 PM ETRa Capital Management, L.P.and 3 others13G9.90%6.48M sharesNewApr 21, 2026SEC
Apr 23, 20268:42 PM ETOrbiMed Advisors LLCand 3 others13D/A16.00%12.9M shares–Apr 21, 2026SEC
Apr 22, 20264:22 PM ETBaker Bros. Advisors LPand 3 others13D/A15.50%10.3M shares−8.00 ppfrom 23.50%Apr 20, 2026SEC
Feb 13, 20264:02 PM ETVaddi Krishna13G/A13.15%6.75M shares−0.65 ppfrom 13.80%Dec 31, 2025SEC
Nov 7, 20254:01 PM ETIncyte Corp13G9.90%4.37M sharesNewNov 3, 2025SEC
Jun 13, 20255:21 PM ETBaker Bros. Advisors LPand 3 others13D/A23.50%10.3M shares–Jun 12, 2025SEC
May 15, 20255:20 PM ETVaddi Krishna13G/A13.80%6.40M shares+4.30 ppfrom 9.50%Mar 31, 2025SEC
Feb 14, 20254:19 PM ETVaddi Krishna13G/A9.50%5.49M shares–Dec 31, 2024SEC
Feb 13, 20258:58 AM ETFlynn James Eand 3 others13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
Feb 13, 2024UBS Asset Management Americas Inc13G/AOld format–––SEC
Feb 12, 2024Flynn James E13G/AOld format–––SEC
Feb 12, 2024Vaddi Krishna13G/AOld format–––SEC
Jan 10, 2024FMR LLC13G/AOld format–––SEC
Dec 13, 2023Baker Bros. Advisors LP13D/AOld format–––SEC
Nov 13, 2023Flynn James E13GOld format–New–SEC
May 24, 2023Baker Bros. Advisors LP13D/AOld format–––SEC
May 24, 2023OrbiMed Advisors LLC13D/AOld format–––SEC
Feb 13, 2023UBS Asset Management Americas Inc13GOld format–New–SEC
Feb 10, 2023Vaddi Krishna13G/AOld format–––SEC
Feb 10, 2023FMR LLC13G/AOld format–––SEC
Feb 9, 2023FMR LLC13G/AOld format–––SEC
Feb 9, 2022FMR LLC13G/AOld format–––SEC
Feb 4, 2022Vaddi Krishna13G/AOld format–––SEC
Feb 11, 2021Vaddi Krishna13GOld format–New–SEC
Feb 10, 2021FMR LLC13G/AOld format–––SEC
Feb 8, 2021FMR LLC13GOld format–New–SEC
Jan 29, 2021Baker Bros. Advisors LP13D/AOld format–––SEC
Jan 14, 2021OrbiMed Advisors LLC13D/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Prelude Therapeutics Inc shares.

No Form 144 notices for Prelude Therapeutics Inc are on file.